The Dominican Republic is a high-incidence area for multidrug-resistant tuberculosis (MDR-TB; 6.6% of initial cases). Standardised treatment regimens for MDR-TB may be a potential solution. MULTIDRUG-RESISTANT TUBERCULOSIS (MDR-TB), defi ned as Mycobacterium tuberculosis strains with in vitro resistance to the two most effective antituberculosis drugs, isoniazid (INH) and rifampicin (RMP), has become a major barrier to achieving successful tuberculosis (TB) control. 1 Among the estimated 500 000 new MDR-TB cases emerging annually worldwide, most are from low-and middleincome countries. 1,2 There are no randomised clinical trials showing the best drug combinations to achieve cure. Anti-tuberculosis treatment based on secondline drugs (SLDs) is less effective, more costly and associated with more adverse events than fi rst-line regimens. 3, 4 These diffi culties are clearly greater in low-and middle-income countries, which have less access to care and affordable drugs. Even when SLDs are subsidised, programmatic challenges can prevent the completion of the required 18-24 months of treatment. 4 Despite these limitations, by following clinical management principles and with suffi cient programme support, MDR-TB can be treated successfully. 5, 6 Treatment success can vary from <50% 7-9 to >70%. [10] [11] [12] The Dominican Republic is a Caribbean middleincome country with high rates of human immunodefi ciency virus (HIV) co-infection (4.2%-8.3%) in the adult population. 13 The only survey available on drug resistance was published in 1998, where MDR-TB was diagnosed in 6.6% of new TB patients. 14 In April 2005, the World Health Organization (WHO)/ Stop TB Partnership's Green Light Committee (GLC) approved an MDR-TB project in the country. The fi rst patients initiated treatment at the end of August 2006.
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The present article assesses the implementation of MDR-TB treatment under routine low-resource programme conditions in the Dominican Republic in terms of effectiveness, side effects and risk factors associated with poor outcomes.
METHODS
This was a retrospective cohort study of all 289 MDR-TB laboratory-confi rmed patients who started treatment in the Dominican Republic from 29 August 2006 until 30 June 2010. Only patients starting MDR-TB treatment within the programme for the fi rst time were considered. Socio-demographic and clinical features are reported and the time to culture conversion is evaluated. Final treatment outcome (favourable or unfavourable) was available for the 150 patients entering treatment in 2006-2008. For those with favourable outcome, relapse at 6 months after treatment completion was assessed. Other variables evaluated included adverse drug reactions and risk factors for unfavourable outcome. The fl ow chart of enrolment of study patients is shown in Figure 1 .
Drug susceptibility testing (DST) results were available only for failures on Category I or II treatment or cases with persistent TB after treatment in the private sector. Before 2011, the national reference laboratory only had the capacity to test resistance to fi rst-line drugs. Sputum samples were treated with a modifi ed Petroff method and cultured on Löwenstein-Jensen media. DST was performed using the proportion method according to Canetti et al. 15 At baseline, M. tuberculosis isolates were tested for susceptibility to INH (0.2 μg /ml), RMP (40 μg /ml), ethambutol (EMB; 2.0 μg /ml) and streptomycin (4 μg /ml).
Two treatment regimens were used for MDR-TB: 1) the standardised regimen, for patients who had never previously received SLDs, comprised kanamycin (KM), ofl oxacin (OFX), ethionamide, cycloserine and pyrazinamide. 3, 4 EMB was added if DST showed susceptibility. In 2010, OFX was replaced by levofl oxacin and KM by capreomycin (CPM). 2) Individualised regimens were given to those who had received SLDs or if they were in contact with a case who had received SLDs. All individualised regimens were based on at least four drugs that had not been used previously. As many patients had received fl uoroquinolones, only 19 regimens incorporated fl uoroquinolones. All individualised regimens included one injectable (KM or CPM), and most included para-aminosalicylic acid. 3, 4, 16 All treatments were supplemented with vitamin B6 (50 mg). Drugs with unclear effi cacy (Group 5 drugs) 3, 4, 16 and surgery were unavailable.
The length of treatment of both regimens was 18-24 months. All but four of the patients began hospital-based treatment. Anti-tuberculosis medications were given under directly observed treatment (DOT) in the morning without splitting the doses. Patients remained hospitalised until they became sputum smear-negative, and tolerance to drugs was observed. All patients received at least 6 months of an intravenous injectable given daily in the initial phase. Depending on time to culture conversion or lack of adherence to treatment, some cases received the injectable for a longer period. Oral agents were continued throughout the continuation phase. After discharge, patients continued treatment in selected primary health care centres with staff trained in MDR-TB management. Each patient underwent clinical and laboratory evaluations before enrolment, monthly during the initial phase of treatment, including smear and culture, and bimonthly during the continuation phase. Basic baseline laboratory tests included a complete blood count, hepatic and renal function and HIV testing (Determine ® , Abbott Diagnostic Division, Hoofddorp, The Netherlands). Audiometric, psychiatric and ophthalmological evaluations and thyroid stimulating hormone tests were not available.
The main study outcomes were time to culture conversion and whether the patient was cured or completed treatment (favourable outcome) according to defi nitions in international MDR-TB guidelines. 4 A relapse assessment was performed by clinical and bacteriological screening at 3, 6 and 12 months after cure or completion of treatment.
All information used was routine data from clinical records and operational fi les, in accordance with WHO guideline forms and defi nitions. 4 Information was retrospectively reviewed, and data were collected and entered into Excel 2003 (Microsoft, Redmond, WA, USA) by programme staff from January to June 2011. All reported P values were two-sided. P = 0.05 was considered statistically signifi cant. Clinically relevant risk factors were analysed applying Cox proportional hazards model to generate association estimates with unfavourable outcome and 95% con fi dence intervals (CIs). The proportionality of risks in the Cox models were verifi ed using Schoenfeld plots. 17 Analyses were performed using R statistical package, version 2.12.1 (R Foundation for Statistical Computing, Vienna, Austria).
Ethics committee approval
Ethical approval was provided by the local authorities and by the Ethics Advisory Group of the International Union Against Tuberculosis and Lung Disease.
RESULTS
A total of 289 MDR-TB patients were included. The median age was 31 years (interquartile range [IQR] Most of the patients were from Santo Domingo, the capital city (71.6%). Most (72.6%) had previously failed treatment, 9.7% had relapsed and 3.5% had defaulted from treatment; 7.6% were new incident MDR-TB cases. A high proportion of the sample population (15.9%) were contacts of MDR-TB patients. Approximately 7% had no information on previous treatment, as most were from the private sector. At least 37 patients had used SLDs in the past, particularly fl uoroquinolones. Twelve (4.5%) were HIV-infected. Illicit substance abuse was recorded for 34 (11.8%) and 24 (8.3%) had a history of incarceration. On chest X-ray, 78.2% of the patients had cavitation, and for the 259 with an available haemoglobin test, levels were low in 57.1% (<13 g /dl for men and <12 g /dl for women, Table 1 ).
The median time between requesting DST and starting treatment was 7.3 months (IQR 5.4-14.2); however, this delay steadily decreased over the years. Most patients were treated using a standardised regimen (81.7%). Culture conversion was obtained in 250 patients (86.5%). The median time to culture conversion was 2 months (IQR 2-3), and 78.6% of patients had achieved culture negativity by the fourth month. There were no statistically signifi cant differences in speed of conversion as regards type of regimen or year of treatment. Among the 39 cases (13.5%) who did not convert, 17 were early deaths, 10 defaulted from anti-tuberculosis treatment, and one completed treatment (MDR-TB confi rmed by biopsy). Only 11 of those who did not convert were assumed to be failures (nine of these were from the early cohorts, [2006] [2007] [2008] Treatment effi cacy was calculated as the sum of cured + treatment completed divided by the sum of cured + treatment completed + failures. According to the results for the 150 patients with fi nal outcomes, overall treatment effi cacy was 89%. The effi cacy of the individualised regimen was 81%, while the effi cacy of the standardised regimen was 92.8% (P = 0.056).
Unfavourable outcomes (defi ned as death, failure or default) occurred in 28% of the 150 patients: 11.3% died, 8.7% failed and 8% defaulted. Death occurred at a median of 7 months after initiating treatment (IQR 3-7), default mostly occurred at 7.5 months (IQR 3.25-17), and failure occurred mainly at 14 months (IQR 12.5-20.5). Among the two HIVinfected cases, one was cured and the other defaulted.
In univariate analysis (Appendix Table A .1), culture conversion after >2 months was found to predict an unfavourable outcome, with a hazard ratio of 2.65 (95%CI 1.37-5.29, P = 0.005). Low haemoglobin and bilateral cavitation on chest X-ray were also predictive of an unfavourable outcome, but with borderline signifi cance. After adjusting for potential confounders in the fi nal multiple regression model, conversion after >2 months (P = 0.011) and bilateral cavities (P = 0.031) were signifi cantly associated with unfavourable outcome (Appendix Table A .1). All but two patients reported some kind of adverse event, with a median of fi ve side effects per patient (IQR 3-6). Most cases presented mild and manageable adverse events, mainly gastrointestinal disturbances. In only one case did the causative antituberculosis medication need to be suspended (psychotic episode); treatment was resumed without cycloserine once the patient's condition had stabilised. A complete description and frequency of the side effects are shown in Appendix Table A A relapse assessment was performed in the 108 patients with a favourable outcome. At least 6 months of follow-up was considered acceptable; 18 however, 83.3% were followed for >1 year (range 8-34 months). Of these patients, 100 were asymptomatic, 4 died, 2 were symptomatic and 2 were lost to follow-up. Overall, only one case was confi rmed as an MDR-TB relapse.
DISCUSSION
The question of whether national TB programmes should invest in SLDs and MDR-TB management has been widely discussed. 19 Only when MDR-TB was recognised as a global epidemic was there a need to face this problem under programme conditions. 20 Our experience in the Dominican Republic, working under programme conditions with many limitations, can be considered encouraging, as the country has achieved treatment successes (72%) comparable to the best experiences published to date with individualised management in reference and high-resource settings. 10, 12, [21] [22] [23] [24] [25] Moreover, the success rates are higher than that estimated for GLC-approved programmes (60%), 22 and higher than those gathered in the two meta-analyses analysing MDR-TB treatment outcomes. 5, 6 In the meta-analysis published by Johnston et al., 5 including 31 programmes from 21 countries, a treatment success rate of 62% (95%CI 57-67) was achieved, while in the meta-analysis published by Orenstein et al., studies that combined treatment duration of at least 18 months and DOT throughout had signifi cantly higher pooled success rates (69%) than those who did not (58%). 6 Our experience seems to confi rm these results, as the use of DOT and prolonged treatment achieved a similar outcome (72%). Conversely, our experience achieved higher results with standardised regimens than those reported in the meta-analysis (74.2% vs. 54%), while patients in our study who received individualised treatment achieved similar outcomes (66% vs. 64%). At the time of the study, access to some SLDs was limited and high-dose fl uoroquinolones were not indicated. Patients receiving individualised treatment may have had M. tuberculosis strains with a more extensive pattern of resistance. All of these factors could have contributed to the relatively reduced effectiveness of individualised regimens.
Before 2010, patients waited many months to enter into treatment. Some died during the delay, and the rest were aware of that. This may be why our patients were particularly adherent and able to endure side effects. In addition, as these patients had lived with the disease for many years, some kind of survival effect may have existed.
Regarding the effi cacy of the regimens used, our overall result of 89% is among the highest published. 3 The median time to achieve culture negativity, also a refl ection of effi cacy, was as early as 2 months (IQR 2-3), similar to the 58-99 days published in the TBNET (Tuberculosis European Network) systematic review. 26 The effectiveness of the regimen might have been even better, with fewer deaths and defaults, had intensive care and social support accompanied the treatment.
In the multivariate analysis, only conversions that took place after 2 months (P = 0.008) and bilateral cavities (P = 0.032), factors not usually analysed in other studies, were signifi cantly associated with unfavourable outcome. Bilateral cavitation was linked to death (15%) and failures (10%), while culture conversion after 2 months was found to be an even stronger risk factor for both (15.6% death, 16.9% failures). Borderline signifi cance was obtained for low haemoglobin (P = 0.075), which has been shown to be a worse outcome predictor in other studies. 10, 23 Using an EMB-containing standardised regimen also acted as a borderline signifi cant risk factor (P = 0.054). Nonetheless, we believe that adding EMB was not in itself a risk factor for defaulting, but a result of residual confounding.
The anarchic use of SLDs in the past was notably frequent in the early years of implementation. The use of individualised regimens fell from 58.3% in 2006 to only 16% in 2010. It appears that the introduction of MDR-TB treatment by the National Tuberculosis Control Programme has reduced the uncontrolled use of anti-tuberculosis SLDs, making individualised regimens, which are often more lengthy and much more expensive, less necessary. The proportion of side effects (median fi ve per patient) observed was greater than in other studies, 27,28 but treatment had to be interrupted for only one patient. Aggressive treatment of side effects and correct drug dosages might have been crucial in preserving treatment activity.
The current study is subject to several limitations, mainly due to use of routine data and resource constraints. Some key information, such as the number of drugs to which each patient was resistant and other potential risk factors, is missing, and data on specifi c causes of death or default during treatment were unavailable. However, other typical factors associated with worse outcome in MDR-TB management were probably not signifi cant due to the size of our population. The relapse assessment was performed with many restrictions and with inconsistent availability of culture confi rmation in asymptomatic patients. Furthermore, the lack of funding made it impossible to assess the role of reinfection. Nonetheless, the use of routine data and fi eld limitations do not diminish the interest of the fi ndings; on the contrary, they bring them closer to the reality of MDR-TB in low-and middle-income countries.
In conclusion, based on programme conditions and with effective standardised treatment, successful, low-cost MDR-TB management can be achieved even in resource-constrained settings with high initial MDR-TB rates. The overall 86.4% culture conversion and 74.3% treatment success rates achieved with standardised treatment regimens in the Dominican Republic are good examples. ii The International Journal of Tuberculosis and Lung Disease EMB susceptibility, sex and number of side effects also disrupted the proportionality of the analysis, and were not included. HR = hazard ratio; CI = confidence interval; SLD = second-line drugs; BMI = body mass index; CXR = chest X-ray; EMB = ethambutol.
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